Operating cash flow was -$18.8M in 2026Q2 and free cash flow margin was -100.5%, with cash burn largely funded by a $136.0M cash balance rather than internally generated cash.
Xilio Therapeutics, Inc. (XLO) cash flow statement — 7-year operating, investing & financing cash flows
| Metric | TTM | Dec'25 | Dec'24 | Dec'23 | Dec'22 | Dec'21 | Dec'20 | Dec'19 |
|---|
| Cash from Operations | -56.9M | -4.99M | -18.38M | -68.62M | -75.72M | -80.75M | -36.09M | -17.84M |
| Operating CF Margin % | - | -11.41% | -289.69% | - | - | - | - | - |
| Operating CF Growth % | -99.66% | 72.84% | 73.22% | 9.38% | 6.23% | -123.74% | -102.27% | - |
| Net Income | -11.49M | -35.04M | -58.24M | -76.4M | -88.22M | -75.8M | -55.22M | -17.31M |
| Depreciation & Amortization | 1.32M | 1.54M | 1.64M | 1.9M | 1.85M | 1.5M | 1.06M | 240K |
| Stock-Based Compensation | 8.66M | 6.94M | 6.43M | 7.38M | 8.42M | 4.96M | 1.3M | 112K |
| Deferred Taxes | 0 | 0 | 0 | 0 | 0 | 222K | 0 | -1.74M |
| Other Non-Cash Items | -23.77M | -3.56M | 3K | 160K | 224K | 173K | 165K | 56K |
| Working Capital Changes | -31.61M | 25.13M | 31.78M | -1.66M | 2M | -11.8M | 16.6M | 797K |
| Change in Receivables | 22.5M | -5M | 0 | 0 | 0 | 0 | 0 | 0 |
| Change in Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Change in Payables | -1.54M | 152K | 1.53M | -2.06M | 485K | -2.82M | 2.93M | 970K |
| Cash from Investing | -728K | -518K | -36K | -486K | -1.87M | -1.1M | -2.19M | -715K |
| Capital Expenditures | -728K | -518K | -36K | -486K | -1.87M | -1.1M | -2.19M | -715K |
| CapEx % of Revenue | 1.32% | 1.18% | 0.57% | - | - | - | - | - |
| Acquisitions | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Investments | - | - | - | - | - | - | - | - |
| Other Investing | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Cash from Financing | 76.07M | 87.78M | 29.2M | -6.55M | -69K | 260.67M | 10.03M | 60.02M |
| Debt Issued (Net) | 0 | 0 | -3.38M | -6.75M | -85K | -110K | -99K | 9.95M |
| Equity Issued (Net) | 77.62M | 87.78M | 6.83M | 202K | 16K | 261.25M | 9.97M | 60.02M |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Share Repurchases | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Financing | -1.55M | 0 | 25.75M | 0 | 0 | -467K | 159K | -9.95M |
| Net Change in Cash | 18.44M | 82.27M | 10.78M | -75.68M | -77.67M | 178.82M | -28.25M | 41.46M |
| Free Cash Flow | -57.63M | -5.51M | -18.41M | -69.11M | -77.59M | -81.85M | -38.28M | -18.56M |
| FCF Margin % | -104.75% | -12.59% | -290.26% | - | - | - | - | - |
| FCF Growth % | -227.79% | 70.08% | 73.35% | 10.93% | 5.21% | -113.83% | -106.27% | - |
| FCF per Share | -2.93 | -0.66 | -4.82 | -35.19 | -39.65 | -204.40 | -1023.15 | -634.77 |
| FCF Conversion (FCF/Net Income) | 5.02x | 0.14x | 0.32x | 0.90x | 0.86x | 1.07x | 0.65x | 1.03x |
| Interest Paid | 0 | 0 | 62K | 0 | 0 | 492K | 536K | 14K |
| Taxes Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Quick answers to the most common questions about buying XLO stock.
Xilio Therapeutics, Inc. (XLO) generated $-5.0M in net cash from operating activities in 2025. This reflects the cash generated directly from core business operations.
Xilio Therapeutics, Inc. (XLO) reported negative free cash flow of $5.5M in 2025, indicating capital requirements exceeded cash from operations.
Xilio Therapeutics, Inc. (XLO) spent $0.5M on capital expenditures in 2025. CapEx represents the cash invested in physical assets like property, plant, and equipment to maintain or grow the business.
Key Metrics
Top Statement Risk
Cash burn against lumpy receipts
Metrics are mathematically derived from official filings.
Operating Cash Diverges From Reported Earnings
Based on the reported quarterly figures, XLO's operating cash flow tracked net income in direction only intermittently, with the ratio swinging from roughly -2.18 in 2025Q1 to 2.94 in 2026Q2, which signals earnings that are poorly anchored to cash generation.
The 2025Q1 quarter shows positive operating cash flow of $29.0M against a net loss of $13.3M, while 2026Q2 shows operating cash outflow of $18.8M against a net loss of $6.4M, so the conversion ratio is driven more by working capital timing than by underlying profitability. Net income in 2025Q4 of $10.4M was accompanied by operating cash outflow of $2.0M, a pattern that suggests reported profit is largely non-cash or collaboration-recognition driven. Investors should monitor whether future cash receipts from collaborations actually arrive in line with recognized revenue, as the current data does not establish that link.
Persistent Free Cash Outflow Despite Episodic Inflows
As reported in the cash flow statements, XLO generated free cash flow of only $29.0M in 2025Q1 against outflows of $10.5M to $22.9M in most other quarters, leaving the ten-quarter trajectory net negative.
Free cash flow margins are deeply negative in most periods, reaching -181.0% in 2026Q1 and -100.5% in 2026Q2 on the reported revenue base, indicating that operating spend is not being covered by collaboration income. The single positive quarter appears to reflect a large working capital release rather than a durable shift in cash economics. Without that release, the business shows a consistent monthly burn profile that warrants close monitoring of runway.
Working Capital Swings Drive Quarterly Results
Based on the reported figures, working capital changes ranged from a $40.2M inflow in 2025Q1 to a $36.3M outflow in 2024Q3, and these swings account for most of the quarter-to-quarter variance in operating cash flow.
The magnitude of working capital movements relative to net income suggests that receivables, deferred revenue, or accrued liabilities are the primary cash timing mechanism rather than operating efficiency. The 2026Q2 working capital outflow of $19.9M, following a $12.1M outflow in 2026Q1, indicates cash absorption that is accelerating rather than reversing. The data does not isolate the individual components, so the specific driver remains unclear and warrants further investigation.
Minimal Capital Intensity Through the Period
As reported in the cash flow data, XLO's capital expenditure remained below $0.6M in every quarter, with CapEx-to-revenue ratios of 0.1% to 5.0%, reflecting an asset-light research model.
Low capital intensity is consistent with a clinical-stage biotechnology profile in which cash consumption is driven by R&D rather than physical assets. Depreciation and amortization of roughly $0.3M to $0.5M per quarter is similarly modest, so maintenance requirements do not appear to weigh on cash flow. The implication is that cash burn is an operating expense question, not a capital allocation one.
Stock-Based Compensation Flatters Cash Burn
Based on the reported figures, stock-based compensation of $1.1M to $2.9M per quarter is a non-cash add-back, so the reported operating cash burn understates the economic cost of employee compensation.
Because SBC is excluded from operating cash flow, shareholders bear a dilution cost that does not appear in the cash burn figures, which may make the business look less expensive than it is on an owner-economics basis. The working capital inflows that offset burn in certain quarters may also reflect timing of collaboration receipts rather than sustainable cash generation. Investors should weigh these items together when judging runway, and should not treat the single positive cash quarter as evidence of self-funding capacity.